Literature DB >> 21692708

Colorectal cancer vaccines in clinical trials.

Frank M Speetjens1, Eliane C M Zeestraten, Peter J K Kuppen, Cornelis J M Melief, Sjoerd H van der Burg.   

Abstract

This article elucidates current strategies of active immunotherapy for colorectal cancer patients with a focus on T-cell mediated immunotherapy. Poor prognosis of especially stage III and IV colorectal cancer patients emphasizes the need for advanced therapeutic intervention. Here, we refer to clinical trials using either tumor cell-derived vaccines or tumor antigen vaccines with a special interest on safety, induced immune responses, clinical benefit and efforts to improve the clinical impact of these vaccines in the context of colorectal cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21692708     DOI: 10.1586/erv.11.63

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  11 in total

1.  Gab2 is a novel prognostic factor for colorectal cancer patients.

Authors:  Chenbo Ding; Junmin Luo; Weina Yu; Shaoying Gao; Liwen Yang; Chao Chen; Jihong Feng
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

2.  Upregulation of TSPAN12 is associated with the colorectal cancer growth and metastasis.

Authors:  Jiao Liu; Chuang Chen; Guang Li; Dechang Chen; Qingshan Zhou
Journal:  Am J Transl Res       Date:  2017-02-15       Impact factor: 4.060

Review 3.  T-cell-inducing vaccines - what's the future.

Authors:  Sarah C Gilbert
Journal:  Immunology       Date:  2012-01       Impact factor: 7.397

4.  Investigation of phosphorylated adjuvants co-encapsulated with a model cancer peptide antigen for the treatment of colorectal cancer and liver metastasis.

Authors:  Tyler J Goodwin; Leaf Huang
Journal:  Vaccine       Date:  2017-04-03       Impact factor: 3.641

5.  Gab2 facilitates epithelial-to-mesenchymal transition via the MEK/ERK/MMP signaling in colorectal cancer.

Authors:  Chenbo Ding; Junmin Luo; Longmei Li; Shanshan Li; Liwen Yang; Hongfei Pan; Qianyi Liu; Huan Qin; Chao Chen; Jihong Feng
Journal:  J Exp Clin Cancer Res       Date:  2016-01-12

6.  Clinicopathological significance of SPC18 in colorectal cancer: SPC18 participates in tumor progression.

Authors:  Takuya Hattori; Kazuhiro Sentani; Oue Naohide; Naoya Sakamoto; Wataru Yasui
Journal:  Cancer Sci       Date:  2017-01       Impact factor: 6.716

7.  Elevated Gab2 induces tumor growth and angiogenesis in colorectal cancer through upregulating VEGF levels.

Authors:  Chenbo Ding; Junmin Luo; Xiaobo Fan; Longmei Li; Shanshan Li; Kunming Wen; Jihong Feng; Guoqiu Wu
Journal:  J Exp Clin Cancer Res       Date:  2017-04-18

Review 8.  Strategies for developing and optimizing cancer vaccines.

Authors:  Hoyoung M Maeng; Jay A Berzofsky
Journal:  F1000Res       Date:  2019-05-13

9.  PPM1D is a prognostic marker and therapeutic target in colorectal cancer.

Authors:  Tian-Shu Peng; Yong-Heng He; Tian Nie; Xiang-Dang Hu; Hai-Yan Lu; Jian Yi; Yun-Fei Shuai; Min Luo
Journal:  Exp Ther Med       Date:  2014-06-06       Impact factor: 2.447

Review 10.  The Immunogenicity of Colorectal Cancer in Relation to Tumor Development and Treatment.

Authors:  Natasja L de Vries; Marloes Swets; Alexander L Vahrmeijer; Marianne Hokland; Peter J K Kuppen
Journal:  Int J Mol Sci       Date:  2016-06-29       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.